Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. Fundamental Analysis
Regeneron Pharmaceuticals, Inc. (REGN) shows moderate financial fundamentals with a PE ratio of 17.77, profit margin of 31.41%, and ROE of 14.83%. The company generates $14.5B in annual revenue with moderate year-over-year growth of 8.27%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 82.2/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze REGN's fundamental strength across five key dimensions:
Efficiency Score
ExcellentREGN demonstrates superior asset utilization.
Valuation Score
ExcellentREGN trades at attractive valuation levels.
Growth Score
ExcellentREGN delivers strong and consistent growth momentum.
Financial Health Score
ExcellentREGN maintains a strong and stable balance sheet.
Profitability Score
ModerateREGN maintains healthy but balanced margins.
Key Financial Metrics
Is REGN Expensive or Cheap?
P/E Ratio
REGN trades at 17.77 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, REGN's PEG of -24.13 indicates potential undervaluation.
Price to Book
The market values Regeneron Pharmaceuticals, Inc. at 2.56 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 13.97 times EBITDA. This signals the market has high growth expectations.
How Well Does REGN Make Money?
Net Profit Margin
For every $100 in sales, Regeneron Pharmaceuticals, Inc. keeps $31.41 as profit after all expenses.
Operating Margin
Core operations generate 24.95 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $14.83 in profit for every $100 of shareholder equity.
ROA
Regeneron Pharmaceuticals, Inc. generates $11.11 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Regeneron Pharmaceuticals, Inc. generates strong operating cash flow of $5.03B, reflecting robust business health.
Free Cash Flow
Regeneron Pharmaceuticals, Inc. generates strong free cash flow of $4.12B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $39.66 in free cash annually.
FCF Yield
REGN converts 5.05% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
17.77
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-24.13
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.56
vs 25 benchmark
P/S Ratio
Price to sales ratio
5.64
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.09
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.13
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.15
vs 25 benchmark
ROA
Return on assets percentage
0.11
vs 25 benchmark
ROCE
Return on capital employed
0.10
vs 25 benchmark
How REGN Stacks Against Its Sector Peers
| Metric | REGN Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 17.77 | 29.43 | Better (Cheaper) |
| ROE | 14.83% | 800.00% | Weak |
| Net Margin | 31.41% | -20145.00% (disorted) | Strong |
| Debt/Equity | 0.09 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 4.13 | 4.64 | Strong Liquidity |
| ROA | 11.11% | -17936.00% (disorted) | Strong |
REGN outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Regeneron Pharmaceuticals, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
119.18%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
111.07%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
84.11%
Industry Style: Defensive, Growth, Innovation
High Growth